Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitorsWataru Fukuokaya, Shin Egawa, Takahiro Kimura et al.|Urologic Oncology Seminars and Original Investigations|2022Cited by 24
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus NivolumabYusuke Yano, Haruhito Azuma, Atsuhiko Yoshizawa et al.|Cancers|2022Cited by 21
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan ConsortiumTaizo Uchimoto, Haruhito Azuma, Kengo Iwatsuki et al.|International Journal of Clinical Oncology|2024Cited by 12
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial CarcinomaTaizo Uchimoto, Haruhito Azuma, Takuya Matsuda et al.|Targeted Oncology|2024Cited by 12
Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinomaTaizo Uchimoto, Haruhito Azuma, Tatsuo Fukushima et al.|British Journal of Urology|2022Cited by 10